Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of EscharEx-02 for removal of non-melanoma skin lesions
MOH_2021-04-21_009660Phase 2Not yet recruiting
- Sponsor
- ד"ר ירון שהם
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EscharEx-02 in non-melanoma skin cancer (NMSC), actinic keratosis (AK), basal cell carcinoma (BCC) and 1 more, sponsored by ד"ר ירון שהם. Primary endpoints: Safety of EscharEx-02 and Efficacy of lesion removal. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
EscharEx-02
03
Conditions
non-melanoma skin cancer (NMSC)actinic keratosis (AK)basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on MOH_2021-04-21_009660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-21_009660.